Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

By I. Thompson, D. Ankerst, Chen Chi, P. Goodman, C. Tangen, M. Lucia, Ziding Feng, H. Parnes, C. Coltman. Journal of the National Cancer Institute, 2006

970 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d1cf7f1b5d3cefd5cd5ecbba3b2a59fadd0cd490

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Andrew J. Vickers
2. Victor M. Montori

In Pulmonary and Respiratory Medicine

1. Andrew J. Vickers
2. Hans Lilja
3. Ewout W. Steyerberg

Citations in the corpus

• Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. (2010, methodology): “testosterone treatment (76), but it can only be used for men”
• Prostate-specific antigen and prostate cancer: prediction, detection and monitoring (2008, methodology): “An online calculator, developed by the PCPT investigators, uses PSA and other risk factors to provide a continuous estimate of cancer risk, rather than a binary positive or negative test resul”